Skip to main content

Table 2 Change in HbA1c at 6 months post-initiation of second-line treatment, stratified by baseline HbA1c category

From: Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink

Baseline HbA1c N Mean change at 6 months (standard error) N (%) with fall ≥ 0.5% at 6 months
% mmol/mol % mmol/mol
<7.5 < 58 811 0.02 (0.04) 0.2 (0.4) 277 (34.2)
7.5 to <9.0 58 to <75 2751 −0.71 (0.02) −7.8 (0.2) 1855 (67.4)
9.0 to <10.5 75 to <91 1325 −1.47 (0.04) −16.1 (0.4) 1099 (82.9)
10.5 to <12.0 91 to <108 715 −2.48 (0.06) −27.1 (0.7) 641 (89.7)
≥12.0 ≥108 440 −4.40 (0.12) −48.1 (1.3) 405 (92.1)
Overall   6042 −1.26 (0.02) −13.8 (0.2) 4277 (70.8)
  1. Data from patients who had available HbA1c measurements at 6 months and at baseline, and who were on-treatment at 6 months (i.e. had not switched, intensified or discontinued second-line treatment since the previous time point)